TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02889562

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Study arm that patient can be randomized to. Apixaban is a novel, orally active, potent, direct selective inhibitor of coagulation FXa that directly and reversibly binds to the active site of FXa and exerts anticoagulant and antithrombotic effects by diminishing the conversion of prothrombin to thrombin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Study arm that patient can be randomized to. Warfarin therapy has been the mainstay of therapy for patients with POAF. While the duration of therapy is usually short (3-4 weeks), complications of anticoagulation do occur. Additionally, warfarin therapy for POAF is associated with increased length of stay, need for monitoring, and bleeding complications.
Study: NCT01847911

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self instructed video learning
Description: A complete video lesson of neonatal resuscitation including initial resuscitative maneuvers and administration of ventilation with a SIB and a T-piece resuscitator presented in the primary language of the participating center or university (Spanish or English). A portable kit with a newborn mannequin will be provided for independent video guided practice during the session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: instructor training
Description: a pre-validated OSCE neonatal resuscitation program
Study: NCT03895762

Intervention type: DRUG
Intervention: Abstral Oral Disintegrating Tablet (ODT)
Description: Opioid(Fentanyl)
Study: NCT02979067

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal oxygen flow
Description: Nasal oxygen flow during apnoea

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal oxygen flow
Description: Nasal oxygen flow during apnoea
Study: NCT02395679

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MesoCancerVac
Description: A leukapheresis is performed of which the monocytes are used for differentiation to DCs using specific cytokines. Pulsed autologous DCs (MesoCancerVac) are re-injected 3 times every two weeks. After the third injection with MesoCancerVac, revaccinations to boost the immune system are given after 3 and 6 months.
Study: NCT04329923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine Sulfate 400 mg twice a day
Description: Antimalarial compound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate 600 mg twice a day
Description: Antimalarial compound

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine Sulfate 600 mg once a day
Description: Antimalarial compound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate 600 mg once a day
Description: Antimalarial compound

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo
Study: NCT00299884

Intervention type: DRUG
Intervention: Lipitor 20 mg
Description: A/A for 6 weeks

Intervention type: DRUG
Intervention: Combination Ezetrol 10 mg and Lipidil Supra 160 mg
Description: a/a for 6 weeks
Study: NCT01088815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, nab-Paclitaxel, GDC-0449
Description: 1. One cycle of Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 (28 days cycle) then~2. Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days cycle in combination with oral GDC-0449 150 mg daily
Study: NCT03264638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dingkundan
Description: Dingkundan 7g capsule by mouth, twice daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dingkundan & Diane-35
Description: Dingkundan 7g capsule by mouth, twice daily, and Diane-35 one pill by mouth, once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diane-35
Description: Diane-35 one pill by mouth,once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
Study: NCT00915967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Subjects randomized to the vancomycin group will receive an injection (up to 10 mL) of 5 mg/mL vancomycin administered directly into the wound with a blunt needle following watertight fascial closure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Saline Solution)
Description: Subjects randomized to the saline group will receive an injection (up to 10 mL) of saline solution directly into the wound following watertight fascial closure.
Study: NCT04277702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast 10mg
Description: Oral administration of 10mg of montelukast daily for 12 months

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Description: Percutaneous transluminal angioplasty combined with bare-metal stenting of lower limbs arteries

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Endovascular treatment
Description: Percutaneous transluminal angioplasty combined with bare-metal stenting of lower limbs arteries

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard anti-platelet treatment
Description: Standard antithrombotic treatment for patients undergoing endovascular procedures

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard anti-platelet treatment
Description: Standard antithrombotic treatment for patients undergoing endovascular procedures
Study: NCT04761497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Actice music therapy
Description: active music therapy sessions for three months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Watching nature videos
Description: nature videos sessions for three months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive music therapy
Description: passive music therapy for three months
Study: NCT00906256

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD7295
Description: Capsules 260mg, 455mg, 650mg (single doses), 650mg q12h, 650mg q8h.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04412603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Mirror Therapy
Description: The Conventional Mirror Therapy was carried out with a mirror box and the Mirror Therapy Virtual Reality was carried out with virtual reality glasses and mobile application: Mirror Therapy VR.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Mirror Therapy
Description: The Conventional Mirror Therapy was carried out with a mirror box and the Mirror Therapy Virtual Reality was carried out with virtual reality glasses and mobile application: Mirror Therapy VR.
Study: NCT03514472

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dried Moringa oleifera leaves

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dried Moringa oleifera leaves
Study: NCT03070418

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mini Incision Dynamic Hip Screw Technique
Description: This technique is the same of AO Dynamic Hip Screw (DHS) technique using 4 holes plate or smaller, in this case it is enough to make just a 3 cm skin incision over the guide wire that is inserted parallel to the anteversion wire by using the 135° guide fixed on the T-handle; (step 2-2), and continuing AO technique steps, until step 3-4, for the plate assembling we remove the guide wire, and insert the plate sliding it through the skin cut over the femur shaft under the muscles using the plate for dissection the soft tissue above the bone surface non using any tool as periosteal elevator but the plate itself by holding it from its DHS screw canal and in 180 degree rotation position in axial aspect (transvers aspect) using the plate end for soft tissue gentle dissection over the bone, then turning the plate 180 degree over the bone shaft to the right position and sliding the DHS screw plat canal over the DHS screw using the measuring bar. Two skin stitches are enough.
Study: NCT03693261

Intervention type: PROCEDURE
Intervention: Valve replacement
Description: cardiac surgery for aortic or mitral valve replacement as part of their standard medical care
Study: NCT04321200

Intervention type: DIAGNOSTIC_TEST
Intervention: PANDA Gym
Description: Infants will lie supine on a flat surface and will be placed in the PANDA gym where they either move by themselves or will interact with an instrumented toy. We will collect video, mat, and toy data from PANDA gym under two conditions: 1) infants playing supine without a toy and 2) infants reach, grasp and kick of the new PANDA toy. A test session will proceed as follows: The infant will be placed on his or her back at a predetermined position on the gym mat for the 2-minute no toy condition. Next, the toy will be given to the baby and adjusted for the infant to reach or kick. A caregiver will be seated at the head of the baby (out of a baby's sight) to provide comfort if needed. Testing will be done in NICU or at daycare or the rehabilitation robotics lab at University of Pennsylvania.

Intervention type: DIAGNOSTIC_TEST
Intervention: PANDA Gym
Description: Infants will lie supine on a flat surface and will be placed in the PANDA gym where they either move by themselves or will interact with an instrumented toy. We will collect video, mat, and toy data from PANDA gym under two conditions: 1) infants playing supine without a toy and 2) infants reach, grasp and kick of the new PANDA toy. A test session will proceed as follows: The infant will be placed on his or her back at a predetermined position on the gym mat for the 2-minute no toy condition. Next, the toy will be given to the baby and adjusted for the infant to reach or kick. A caregiver will be seated at the head of the baby (out of a baby's sight) to provide comfort if needed. Testing will be done in NICU or at daycare or the rehabilitation robotics lab at University of Pennsylvania.

Intervention type: OTHER
Intervention: Mobile App
Description: The parent or legal guardian will be consented first via the virtual rounding mobile app. They will also be asked to fill out general surveys including, a demographic survey, and a case report form, and a user feedback survey that provides relevant information, on both the family's and infant's medical history and experience. (see the flow-chart for the app). Within the caregiver survey, we will request the pediatrician (or primary care physician) name. We believe that with the baby name, caregiver name, zip code, and physician name, we will be able to locate the physician if needed.~Parents or legal guardians or the research will be asked to collect video via the MOBILE app. They will be instructed to ensure that the infant lies supine in no more than one-layer of tight-fitting clothing (i.e. infant onesie) while calm and awake. In all cases, we will have video recordings of the baby. They will be asked to upload the video to the app.
Study: NCT04320745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androderm®
Description: Androderm® transdermal dose.
Study: NCT03545880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: A Kinesiotaping will be provided over the upper trapezius muscle after the application of dry needling

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Individuals will not perform any action after the application of trigger point dry needling
Study: NCT04142996

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Theta burst stimulation
Description: Cool B70 coil (left DLPFC) and Cool B65 active/placebo coil (right DLPFC), with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Theta burst stimulation
Description: Cool B70 coil (left DLPFC) and Cool B65 active/placebo coil (right DLPFC), with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Theta burst stimulation
Description: Cool B70 coil (left DLPFC) and Cool B65 active/placebo coil (right DLPFC), with X100 MagPro rTMS Device (Magventure A/S, Farum, Denmark)
Study: NCT01884844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3, Cholecalciferol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02512328

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APP supported colonoscopy preparation
Description: additional usage of an app for colonoscopy preparation
Study: NCT02977416

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anti-TNFα

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anti-TNFα

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anti-TNFα
Study: NCT01457196

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Tumor Genetic Sequencing
Description: This study will look at genetic material from a sample of the subjects tumor, look at certain changes in the genetic material, and see if these changes are related to the subjects cancer.
Study: NCT01891357

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy before and after three weeks of study treatment
Description: Core biopsies for histological analyses, to be analysed by the central pathology

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Study: NCT03883126

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency management
Description: Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions and verified abstinence from alcohol.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency management
Description: Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions and verified abstinence from alcohol.
Study: NCT02818647

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tonsillectomy
Description: Tonsillectomy is the name of the surgery where tonsils are removed via capsullary dissection. There are various techniques and its basically removing the tonsil from its tonsillary fossa and conducting hemostasis with various equipments.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tonsillectomy
Description: Tonsillectomy is the name of the surgery where tonsils are removed via capsullary dissection. There are various techniques and its basically removing the tonsil from its tonsillary fossa and conducting hemostasis with various equipments.
Study: NCT00524095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin and fluticasone
Description: azithromycin 500 mg once a day three times a week for 6 months and then inhaled steroids (fluticasone 500 ug bid) for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone and azithromycin
Description: inhaled steroids (fluticasone 500 ug bid) for 6 months and then azithromycin 500 mg once a day three times a week for 6 months
Study: NCT00557739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate
Description: Topical 0.1% mometasone furoate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate
Description: Topical 0.1% mometasone furoate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mometasone furoate
Description: Topical 0.1% mometasone furoate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nortriptyline HCl
Description: Topical 0.05% or 0.1% nortriptyline HCl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nortriptyline HCl
Description: Topical 0.05% or 0.1% nortriptyline HCl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nortriptyline HCl
Description: Topical 0.05% or 0.1% nortriptyline HCl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nortriptyline HCl
Description: Topical 0.05% or 0.1% nortriptyline HCl
Study: NCT04562272

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LV mechanical unloading by Impella-CP
Description: The patients will receive Impella-CP for 36-48 hours. The pump speed and LV unloading will be guided by PCWP (Swan-Ganz catheter)
Study: NCT00557739

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle (placebo)
Description: Topical placebo
Study: NCT04658368

Intervention type: PROCEDURE
Intervention: Primary TMR
Description: TMR procedure as part of the primary major limb amputation surgery

Intervention type: PROCEDURE
Intervention: Primary TMR
Description: TMR procedure as part of the primary major limb amputation surgery

Intervention type: PROCEDURE
Intervention: Secondary TMR
Description: TMR procedure subsequent to major limb amputation surgery

Intervention type: PROCEDURE
Intervention: Secondary TMR
Description: TMR procedure subsequent to major limb amputation surgery
Study: NCT02656173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Oral tablet
Study: NCT04822558

Intervention type: OTHER
Group type: OTHER
Intervention: Plantar pressure measurement
Description: Biomechanical and clinical evaluation of the reconstructive procedures of ankle and hindfoot using a 3D multisegment foot model

Intervention type: OTHER
Group type: OTHER
Intervention: Gait analysis
Description: Biomechanical and clinical evaluation of the reconstructive procedures of ankle and hindfoot using a 3D multisegment foot model

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ankle and hindfoot reconstruction surgery
Description: Ankle and hindfoot reconstruction surgery
Study: NCT00716937

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: karydakis flap
Description: Karydakis flap is a type of primary repair of the wound, after complete excision of sacral pilonidal cyst with 2 characteristics 1)lateralization of final scar 2)flattening of natal cleft

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: karydakis flap
Description: Karydakis flap is a type of primary repair of the wound, after complete excision of sacral pilonidal cyst with 2 characteristics 1)lateralization of final scar 2)flattening of natal cleft

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laying open
Description: laying open the site of excision of sinus or cyst without any flap
Study: NCT03722680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: Riluzole during chemotherapy (oxaliplatin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo
Study: NCT04281537

Intervention type: DRUG
Intervention: Enzyme Replacement Therapy (ERT)
Description: ERT infusion every other week
Study: NCT04919486

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: visual feedback with non-weight bearing exercise
Description: the training time is 12 weeks, twice a week, 60 minutes each time, a total of 24 times.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: elastic band exercise
Description: the training time is 12 weeks, twice a week, 60 minutes each time, a total of 24 times.
Study: NCT00846170

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: co-biotic
Description: give probiotic 2 t/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo 2T/day
Description: cross over of patients from study arm to placebo arm
Study: NCT01467245

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypercapnia during thoracoscopy
Description: keyhole surgery through the chest for repair of oesophageal atresia with tracheo-oesophageal fistula or congenital diaphragmatic hernia in neonates

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open surgery
Description: open surgery for repair of oesophageal atresia with tracheo-oesophageal fistula or congenital diaphragmatic hernia in neonates
Study: NCT01484938

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPTI-FREE PureMoist
Description: Commercially marketed multi-purpose contact lens solution for cleaning, rinsing, disinfecting/storing, and reinserting contact lenses
Study: NCT03397654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab solution

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Trans-arterial chemoembolization
Description: Doxorubicin injected through the hepatic blood supply directly to the cancer-affected part of the liver, then gelatin sponge particles injected to block the blood vessels supplying the tumour
Study: NCT02140775

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Counseling
Description: Behavioral Activation counseling is a manualized intervention adapted from a behavioral activation treatment for depression (BAT-D) and provides a basic foundation for behavior change. The individual sessions last one hour and are scheduled every two weeks. The counseling offers a brief, structured approach to identifying and scheduling activities in life areas to reduce avoidant behavior and increase activity level with the goal of achieving employment or enroll in training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Activation Counseling
Description: Behavioral Activation counseling is a manualized intervention adapted from a behavioral activation treatment for depression (BAT-D) and provides a basic foundation for behavior change. The individual sessions last one hour and are scheduled every two weeks. The counseling offers a brief, structured approach to identifying and scheduling activities in life areas to reduce avoidant behavior and increase activity level with the goal of achieving employment or enroll in training.
Study: NCT02710500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAAVrh74.MHCK7.DYSF.DV
Description: Biological/Vaccine: rAAVrh74.MHCK7.DYSF.DV Recombinant adeno-associated virus carrying a dysferlin transgene under control of a muscle specific MHCK7 promoter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAAVrh74.MHCK7.DYSF.DV
Description: Biological/Vaccine: rAAVrh74.MHCK7.DYSF.DV Recombinant adeno-associated virus carrying a dysferlin transgene under control of a muscle specific MHCK7 promoter.